|
Name |
Shamixanthone
|
Molecular Formula | C25H26O5 | |
IUPAC Name* |
(1R,2S)-1,11-dihydroxy-5-methyl-8-(3-methylbut-2-enyl)-2-prop-1-en-2-yl-2,3-dihydro-1H-pyrano[3,2-a]xanthen-12-one
|
|
SMILES |
CC1=CC2=C(C3=C1OC[C@@H]([C@H]3O)C(=C)C)C(=O)C4=C(C=CC(=C4O2)CC=C(C)C)O
|
|
InChI |
InChI=1S/C25H26O5/c1-12(2)6-7-15-8-9-17(26)19-23(28)20-18(30-25(15)19)10-14(5)24-21(20)22(27)16(11-29-24)13(3)4/h6,8-10,16,22,26-27H,3,7,11H2,1-2,4-5H3/t16-,22-/m1/s1
|
|
InChIKey |
MXGMZMKTWCNKRS-OPAMFIHVSA-N
|
|
Synonyms |
SHAMIXANTHONE; CHEMBL469860; Z41V59XW4A; 35660-46-9; CHEBI:64499; (1R,2S)-1,11-dihydroxy-5-methyl-8-(3-methylbut-2-en-1-yl)-2-(prop-1-en-2-yl)-2,3-dihydropyrano[3,2-a]xanthen-12(1H)-one; (1R,2S)-1,11-dihydroxy-5-methyl-8-(3-methylbut-2-enyl)-2-prop-1-en-2-yl-2,3-dihydro-1H-pyrano[3,2-a]xanthen-12-one; Pyrano(3,2-a)xanthen-12(1H)-one, 2,3-dihydro-1,11-dihydroxy-5-methyl-8-(3-methyl-2-buten-1-yl)-2-(1-methylethenyl)-, (1R,2S)-; Pyrano(3,2-a)xanthen-12(1H)-one, 2,3-dihydro-1,11-dihydroxy-5-methyl-8-(3-methyl-2-butenyl)-2-(1-methylethenyl)-, (1R-trans)-; UNII-Z41V59XW4A; SCHEMBL3133103; DTXSID201045540; BDBM50242273; Q15427832; 11076-08-7
|
|
CAS | 35660-46-9 | |
PubChem CID | 15596091 | |
ChEMBL ID | CHEMBL469860 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 406.5 | ALogp: | 5.9 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 76.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 30 | QED Weighted: | 0.449 |
Caco-2 Permeability: | -4.837 | MDCK Permeability: | 0.00001110 |
Pgp-inhibitor: | 0.786 | Pgp-substrate: | 0.5 |
Human Intestinal Absorption (HIA): | 0.065 | 20% Bioavailability (F20%): | 0.39 |
30% Bioavailability (F30%): | 0.008 |
Blood-Brain-Barrier Penetration (BBB): | 0.009 | Plasma Protein Binding (PPB): | 86.64% |
Volume Distribution (VD): | 0.932 | Fu: | 9.68% |
CYP1A2-inhibitor: | 0.702 | CYP1A2-substrate: | 0.67 |
CYP2C19-inhibitor: | 0.82 | CYP2C19-substrate: | 0.134 |
CYP2C9-inhibitor: | 0.863 | CYP2C9-substrate: | 0.893 |
CYP2D6-inhibitor: | 0.632 | CYP2D6-substrate: | 0.32 |
CYP3A4-inhibitor: | 0.299 | CYP3A4-substrate: | 0.142 |
Clearance (CL): | 2.004 | Half-life (T1/2): | 0.067 |
hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.934 |
Drug-inuced Liver Injury (DILI): | 0.934 | AMES Toxicity: | 0.531 |
Rat Oral Acute Toxicity: | 0.403 | Maximum Recommended Daily Dose: | 0.812 |
Skin Sensitization: | 0.504 | Carcinogencity: | 0.841 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.214 |
Respiratory Toxicity: | 0.197 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC006093 | 0.822 | D0Q0PR | 0.314 | ||||
ENC002916 | 0.822 | D0K8KX | 0.257 | ||||
ENC002623 | 0.766 | D0F7CS | 0.252 | ||||
ENC002651 | 0.724 | D0O1UZ | 0.250 | ||||
ENC002697 | 0.710 | D06GCK | 0.248 | ||||
ENC004145 | 0.657 | D04AIT | 0.239 | ||||
ENC002544 | 0.644 | D0O6KE | 0.234 | ||||
ENC004314 | 0.561 | D0W6DG | 0.228 | ||||
ENC002507 | 0.558 | D0R9WP | 0.221 | ||||
ENC004537 | 0.490 | D04TDQ | 0.219 |